|
Match
|
Document |
Document Title |
|
|
US20090298745 |
Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
The invention provides a method of treatment of diabetes, particularly type II diabetes, or a diabetes related condition, comprising night time dosing of an inhibitor of glycogen phosphorylase,...
|
|
|
US20090298744 |
HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST
Compounds of the present disclosure are fused pyrimidine compounds of formula (I), its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, as...
|
|
|
US20090291112 |
Allograft osteochondral plug combined with cartilage particle mixture
An allograft osteochondral plug is combined with a mixture that includes freeze-milled cartilage particles, and such combination is used to repair defects in articular cartilage. The plug includes...
|
|
|
US20090286715 |
Pharmaceutical Composition
A pharmaceutical composition comprising: (A) a continuous liquid phase; (B) liquid droplets dispersed in said continuous phase; (C) a pharmaceutically-active compound; (D) an enhancer as described...
|
|
|
US20090285771 |
Methods and compositions for needleless delivery of macromolecules
Methods and compositions for needleless delivery of macromolecules to the bloodstream of a subject are provided herein. In one aspect, the invention provides a delivery construct, comprising a...
|
|
|
US20090281020 |
Pharmaceutical Compositions Comprising Dextran With A Molecular Weight Of 1.0-100 KDA And Processes For Their Preparation
A solid or semisolid implant obtainable by providing a liquid composition comprising an aqueous solution of dextran with molecular weight of 1.0-100 kDa and introducing the liquid composition into...
|
|
|
US20090280987 |
Method For Solubilising, Dispersing and Stabilising of Substances, Products Manufactured According To The Method As Well As The Use Thereof
Disclosed is a method in which poloxamer, a resin, and/or a tocopherol is/are fused, and the material that is to be treated is intimately dispersed with said melt. After being introduced into the...
|
|
|
US20090274758 |
Solid Composition for Intra-Oral Delivery of Insulin
The invention provides a solid composition for intra-oral delivery of insulin, comprising; insulin; a hydrophilic polymer matrix; and a phospholipid, providing insulin bioavailability of at least 5%.
|
|
|
US20090264337 |
Cellular GPRS-communication linked glucometer - pedometer
The Cellular GPRS system includes a cellular-based Glucometer (CBG) for blood glucose monitoring, a pedometer for exertion measurement, combined with user-entered dietary or other diabetes-relevant...
|
|
|
US20090264336 |
HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES
Compounds of formula (I)
wherein R 1 , HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the...
|
|
|
US20090258818 |
Compositions For the Treatment of Diabetes
A supramolecular insulin assembly and supramolecular exendin-4 assembly, which is useful as a protein therapeutic agent for the treatment of metabolic disorders particularly diabetes. The...
|
|
|
US20090258817 |
ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are also provided.
|
|
|
US20090252703 |
Use of alcohol co-solvents to improve pegylation reaction yields
Disclosed is a method of producing a composition of matter. The method involves obtaining a pharmacologically active peptide; and conjugating the peptide to a pharmaceutically acceptable...
|
|
|
US20090246283 |
Repeat Sequence Protein Polymer Nanoparticles Optionally Containing Active Agents and Their Preparation
A nanocomposite of a repeat sequence protein polymer, such as a copolymer of silk and elastin, is produced by Supercritical Antisolvent Precipitation with Enhanced Mass Transfer (SAS-EM). The...
|
|
|
US20090239785 |
Insulin Derivative
The present invention relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action. The invention also relates to methods of...
|
|
|
US20090239784 |
Stablised Insulin Compositions
The present invention relates to human insulin analogues having a fast onset of action. These analogues may have amino acid in position B26 substituted with Phe, or be Des(B30) analogues of human...
|
|
|
US20090238886 |
Retro-Inversion Peptides That Target GIT Transport Receptors and Related Methods
Retro-inverted forms of GIT targeting agents that target specific receptor sites in vivo and/or promote uptake of active agents and/or enhance active site delivery across the GIT into the systemic...
|
|
|
US20090232870 |
APPARATUS AND METHOD OF RETAINING AND RELEASING MOLECULES FROM NANOSTRUCTURES BY AN EXTERNAL STIMULUS
An apparatus and method for using nanostructures, such as nanopores, nanofibers, nanowells, or nanocones as carriers for drugs, biomarkers and/or biomolecules. The apparatus and method for use on...
|
|
|
US20090220562 |
Osteogenic and anti-adipogenic oxysterols
The present invention discloses osteogenic and anti-adipogenic oxysterols. Agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative...
|
|
|
US20090220452 |
Method Of Producing A Modified (POLY) Peptide
This invention relates to a method of producing a modified (poly)peptide, said method comprising the step of modifying in an organic solvent a crown ether-bound (poly)peptide at one or more...
|
|
|
US20090220451 |
CYCLOPROPYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
|
US20090220435 |
TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS
Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and...
|
|
|
US20090215669 |
COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES
The present invention relates to a composition comprising a peptide of the formula: (Xaa) n1 -Xaa 1 -His-Thr-Asp-(Xaa) n2 wherein Xaa is any amino acid; Xaa 1 is a hydrophobic amino acid; n 1 is...
|
|
|
US20090214657 |
Orally Absorbed Pharmaceutical Formulation and Method of Administration
A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound...
|
|
|
US20090214507 |
METHOD OF TREATING PREVENTING, INHIBITING OR REDUCING DAMAGE TO CARDIAC TISSUE
A method of treatment for treating, preventing, inhibiting or reducing damage to coronary tissue includes inducing at least one of a physiological function selected from: up-regulation of or...
|
|
|
US20090214468 |
Localized Insulin Delivery for Bone Healing
A method of promoting bone healing in a non-diabetic patient in need thereof by locally administering a therapeutically effective amount of insulin to the patient. A drug delivery device, which...
|
|
|
US20090208511 |
Novel method for identifying diabetic patients at increased risk for pathological complications
The present invention provides methods for detecting and measuring, in a sample from a subject, the plasma levels of endothelial cell antibodies to diagnose an increased risk of pathological...
|
|
|
US20090203576 |
METHODS AND COMPOSITONS FOR PULMONARY DELIVERY OF INSULIN
Systemic delivery of insulin to a mammalian host is accomplished by inhalation of a dry powder of insulin. It has been found that dry insulin powders are rapidly absorbed through the alveolar...
|
|
|
US20090202659 |
Modulation of Peripheral Clocks in Adipose Tissue
Genes encoding the transcription factors controlling the core circadian oscillator (BMAL, Clock, NPAS, Per) and their regulatory targets (Rev-erbα, Rev-erb) have been found in adipose tissue. The...
|
|
|
US20090202628 |
Nanoparticles for protein drug delivery
The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced...
|
|
|
US20090202620 |
POLYMER-STABILIZED LIPOSOMAL COMPOSITIONS AND METHODS OF USE
The invention provides liposomal particle compositions, which incorporate a lipophilic biodegradable polymer, such as amino acid-containing polyester amide (PEA), polyester urethane (PEUR), and...
|
|
|
US20090202481 |
Composition for Sustained Release Delivery of Proteins or Peptides
The present invention provides a novel liquid composition suitable for in-situ formation of a depot system to deliver a protein or peptide in a controlled manner. The composition of the present...
|
|
|
US20090192073 |
METHOD FOR PRODUCING INSULIN ANALOGS HAVING A DIBASIC B CHAIN TERMINUS
The invention relates to a method for producing a type of insulin by genetically engineering a precursor thereof and converting said precursor to the respective insulin in an enzyme-catalyzed...
|
|
|
US20090185976 |
METHOD FOR INTRODUCING A CHEMICAL AGENT INTO THE SYSTEMIC CIRCULATION
A method for introducing a drug, imaging agent and/or other chemical agent into the systemic circulation comprises providing a the drug, imaging agent and/or other chemical agent in liposomes...
|
|
|
US20090176692 |
AMIDATED INSULIN GLARGINE
The invention relates to insulin glargine which is modified by amidation, especially Gly (A21), Arg (B31), Arg amide (B32) human insulin (insulin glargine amide).
|
|
|
US20090176691 |
Pharmaceutical Compositions Containing at Least One Protein Active Ingredient Protected From Digestive Enzymes
The present invention relates to pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes. Said pharmaceutical compositions contain said at...
|
|
|
US20090175821 |
Modified therapeutic peptides with extended half-lives in vivo
A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid...
|
|
|
US20090169640 |
COMPOSITONS FOR NASAL ADMINISTRATION OF PHARMACEUTICALS
Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a...
|
|
|
US20090156464 |
Pharmaceutical Compositions and Methods for Insulin Treatment
Compositions and methods for treating a patient with insulin that combines insulin, a permeation enhancer, and a carrier that maintains an acidic pH, are disclosed.
|
|
|
US20090143763 |
ROTATABLE INFUSION SET
An arrangement for introducing a liquid into the body of a patient or for withdrawing a liquid from the body of a patient, including a first structural part carrying a cannula for positioning in...
|
|
|
US20090137455 |
RAPID ACTING AND LONG ACTING INSULIN COMBINATION FORMULATIONS
An injectable formulation containing a combination of a rapid acting insulin and a long acting insulin has been developed wherein the pH of the rapid acting insulin is adjusted so that the long...
|
|
|
US20090137454 |
Insulin Derivatives
The present invention is related to insulin derivatives having a side chain attached to an ε-amino group of a Lys residue present in the A-chain or to an ε-amino group of a Lys residue in the...
|
|
|
US20090110742 |
Long-acting colloidal insulin formulation and its preparation
The invention relates to injectable long-acting insulin formulations for the treatment of types I and II diabetes in humans and animals. The essential object of the invention is to provide an...
|
|
|
US20090110661 |
Novel Gene Therapy Approach For Treating The Metabolic Disorder Obesity
The present application relates to novel methods for treating obesity. Some aspects pertain to the use of gene therapy to treat diseases related to metabolic dysfunction, such as diabetes, obesity,...
|
|
|
US20090110644 |
Polymer nanoparticles coated by magnetic metal oxide and uses thereof
The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the...
|
|
|
US20090105121 |
Insulin Derivative
The present invention relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action.
|
|
|
US20090104275 |
Nanoencapsulation of Proteins
The protein encapsulation via entrapping protein in CaCO 3 microparticles followed by polymeric shell deposition can be used for vaccination based on protein antigen, and in particular rPA 102.
|
|
|
US20090099434 |
OXYGEN-EFFECT FREE ANALYTE SENSOR
The present invention provides an electrochemical sensor having a sensing chemistry that operates substantially free of any “oxygen effect”. The electrochemical sensors are useful in...
|
|
|
US20090099065 |
Acylated Single Chain Insulin
The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue...
|
|
|
US20090099064 |
Derivatized insulin oligomers
The present invention provides oligomers of phosphorylated insulin and formulations thereof. The oligomeric derivatives of the invention exhibit pharmacodynamic properties that are significantly...
|